Sterling Technology | Virtual Data Rooms’ Post

Are you ready for a digital-first future in #lifesciences dealmaking? Transactions involving digital assets are an increasing focus for #pharmaceuticals, #medicaldevice and #medtech companies. In our podcast series, life sciences industry M&A veteran John Easton discusses how these differ from traditional life science deals, and what both acquiror and target should look out for to increase the chances of deal success, mitigate risks and avoid failure. In previous episodes, we’ve covered key areas of difference between traditional life science transactions and the new world of digital dealmaking including corporate culture, information governance, defining and valuing the asset, and due diligence. In this fifth and final conversation, we pull these strands together and discuss how they influence transaction structure and terms – which both parties must agree on to bring any deal to a successful conclusion. To listen, follow the link at the bottom. You can also download the report accompanying the series. Essential information for life sciences dealmakers seeking to navigate an unfamiliar terrain of transactions involving #artificialintelligence, #machinelearning and #bigdata, our five-part series and accompanying report provide insights into differences between digital and traditional deals in key areas including corporate culture, data privacy, intellectual property, asset valuation, due diligence and deal structuring. #mergersacquisitionsdivestitures #privateequity #venturecapital #corporatefinance https://lnkd.in/eFJsDmw8

🎙 Dive into Sterling Technology | Virtual Data Rooms new podcast series with industry veteran John Easton. Discover how digital assets are transforming transactions in Life Science. Gain key insights on deal success and risk mitigation. Don't miss out! 🎙

How can biotechs focus resources to reach market faster and generate revenue earlier? The early steps your team can take are simpler than you may think. While the questions are complex - how to maximize efficiency, minimize downtime, and drive faster decision-making - there are relatively straightforward changes you can make today, that will compound significantly over time. The other week, I chatted with Carina Clingman, PhD on Building Biotechs, about this exact topic. We covered things like: - Being explicit about what the goals are + communicating this with your team. - Avoiding unbound experiments or shiny object syndrome. What is that critical piece of data you need to generate and what specific studies do you need to run? - Working backwards from a long-term end goal, and breaking it down into manageable, shorter term pieces. - Putting yourself in the shoes of the people reporting to you. Asking things like: "What does their process/work look like? Can I make it easier for them?" - Understanding R&D costs. Calculating eg how much a month of R&D costs, and therefore how much X time savings is worth to you and your team. Check out the episode here: https://lnkd.in/eP2TYaF6 Links to other platform in the comments section below.

The clock is ticking as we stand on the brink of a new era in Industry 5.0! ⏰ Don’t miss the chance to engage with industry leaders at the #ScilifeSmartQualitySummit2024, where they’ll share best practices for you to instantly apply to your quality processes to get ahead. We are excited to feature Harsh Thakkar, CEO and founder of Qualtivate, a quality, compliance, technology and data management consulting firm, helping some of the fastest growing start ups in the world. He will be joined by Lesley Worthington and Karen Taylor. This power trio will dive into the evolution from Industry 4.0 to 5.0, exploring how life sciences can lead the charge with forward-thinking, sustainable, and human-centric strategies. Here’s what’s on the agenda: ✦ Leveraging AI to enhance resilience in life sciences ✦ Designing sustainable and resilient supply chains ✦ Prioritizing human needs in technology-driven advancements 💬 Get ready for transformative insights that will empower you to take bold steps in redefining your organizational strategy and impact. 📅 14 NOV | 15:00 CET | 9:00 EST 🌐 VIRTUAL EVENT Seize this opportunity—register now to be part of the future >> https://bit.ly/3xS1s1p #LifeSciences #Pharma #MedicalDevices #Compliance

Are you a biotech co having trouble "breaking through the noise" (a.k.a. capturing investors' attention)? Check out this analysis 📊📈🔍from our editor-in-chief: "Rising above the noise: hallmarks of Europe’s leading innovation - Business models, technologies and management profiles of European companies that attracted investor or pharma interest during the downturn" Details here: https://lnkd.in/gcJjKcs7 [sub/trial access required] Great insights. Fantastic visuals in the slide deck.

My thanks to Geoff Micks for having me as his guest on a recent edition of the Executive Platforms (EP) BluEPrint podcast. It was great to speak with Geoff about the subject of the themed lunch discussion I facilitated a few months ago at the 2024 Pharma Manufacturing World Summit (PMWS24) on changing the compliance paradigm in large, global companies. It’s a challenge many companies are facing, and our discussion at PMWS24 was a fascinating, open exchange of ideas and approaches employed by different companies. Geoff and I also discussed how quality, regulatory and compliance functions can be more effective and build cultures and processes that support the manufacturing of a wide variety of products. We talked about strategies to accelerate change in large, established companies. Some companies are at different points in their transformation, and hearing from their representatives was inspiring. Geoff and I discussed what it was like working in a company in the medical device and life science industries during COVID, the importance of quality, regulatory and compliance functions having a seat at the table in companies as a full partner, realigning our profession around value creation and success enablement, and how artificial intelligence (AI) will affect our industry. We also spoke about the importance of people in our line of work being bold, not settling for the status quo and having the courage to change and try new ideas. While it can involve a company’s entire workforce, those of us working in quality, regulatory and compliance functions are in a unique position to challenge and improve upon the practices of the past, and make our companies better. That’s exactly what the Quality & Regulatory Affairs team at Thermo Fisher Scientific strives to do every day. 🎥 Watch the full episode here ➡️ https://lnkd.in/ev9YDJeZ Or 🎧 Listen to the full conversation here ➡️ https://lnkd.in/eSHd5Pse #QualityProfessionals #QualityAssurance #RegulatoryAffairs #QARA #Regulatory #Quality #QualityControl #thebluEPrintpodcast #PMWS24 #compliance

Achieve Seamless Information Integration in Life Sciences – Learn how a phased platform-based transformation can bring your teams closer, enhance data sharing, and drive efficiency. Starting with Regulatory processes and extending to Clinical, Quality, and Safety, we have a roadmap for success. Connect with us to explore the possibilities. #DigitalTransformation #LifeSciences

Check out Part 3 – Digital Transformation from our A Story of Innovation series! Discover how PLG Research and Innovation is revolutionizing the life sciences industry with cutting-edge digital and AI solutions in regulatory operations and safety.#Innovation #Healthcare #LifeSciences #PLG #DigitalTransformation #InnovationChronicles

As we progress through September, our company's mission becomes clearer 💪 We are revolutionizing clinical trial success by creating a unified data infrastructure. 🎯Our goal is to empower scientists and medical leaders with advanced data tools and systems, accelerating the development of vital therapies. How are we doing this today? 👉 By reducing data fragmentation and making data accessible in real-time 👉 By empowering Biotechs with user-friendly tools to monitor their trials 👉 By facilitating insight generation and distribution By combining these elements, we're reshaping the traditional drug development approach through a modern technological perspective. Join us in transforming clinical trials and accelerating therapy development. #Clinicaltrials #Datainfrastructure #BiotechInnovation

A rebounding M&A environment, AI investments for productivity and cost reduction, and innovations in digital health and biotechnology were among top themes at the Morgan Stanley Global Healthcare Conference. Learn more below about potential opportunities for investors.